Shared on 08 Nov 25
Fair value Decreased 5.54%PPLPHARMA: New Partnerships Will Drive Future Sector Expansion
Analysts have revised Piramal Pharma's fair value estimate down from ₹258.67 to ₹244.33 per share. This change reflects updated assumptions about revenue growth and profit margins.
Shared on 23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 0.78%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 5.21%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Decreased 1.96%AnalystConsensusTarget has decreased revenue growth from 14.9% to 12.9%, decreased profit margin from 11.2% to 7.5% and increased future PE multiple from 30.4x to 47.2x.
Shared on 19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 12 Mar 25
Fair value Increased 24%AnalystConsensusTarget has decreased future PE multiple from 37.5x to 30.4x.